Human cytomegalovirus (HCMV) is a herpesvirus that infects~ 60% of adults in developed
countries and more than 90% in developing countries. Usually, it is controlled by a vigorous …

Coinfections involving viruses are being recognized to influence the disease pattern that
occurs relative to that with single infection. Classically, we usually think of a clinical …

Late‐onset cytomegalovirus (CMV) disease is a significant problem with a standard 3‐month
prophylaxis regimen. This multicentre, double‐blind, randomized controlled trial compared …

Human cytomegalovirus (HCMV) is a betaherpesvirus with a global seroprevalence of 60–
90%. HCMV is the leading cause of congenital infections and poses a great health risk to …

Viral disease diagnosis has traditionally relied on the isolation of viral pathogens in cell
cultures. Although this approach is often slow and requires considerable technical expertise …

Human cytomegalovirus (CMV), one of the eight herpesviruses that commonly infect
humans, is best known for its propensity to cause disease in immunocompromised patients …

Importance Despite the use of a cytomegalovirus (CMV) prevention strategy of antiviral
prophylaxis for high-risk CMV-seronegative liver transplant recipients with seropositive …

CMV infection is a major cause of morbidity in patients receiving solid organ transplants.
CMV is widely distributed in the general population with seroprevalence ranging from 30 to …

This review will summarize and interpret recent literature regarding the human CMV immune
response, which is among the strongest measured and is the focus of attention for numerous …

Background. Whether the early reduction in cytomegalovirus (CMV) disease seen at 1 year
with prolongation of antiviral prophylaxis (up to 200 days) persists in the long term is …